SARS-CoV-2 emerged as a novel pathogen in 2019. COVID-19 (Coronavirus disease 2019) has affected countries worldwide. Rapid detection of COVID-19 is essential for outbreak management to help mitigate pressures on healthcare services.
Recently, new emerging SARS-CoV-2 variants are of major public concern.
These novel lineages may show increased transmissibility and even bear the risk of immune evasion, therefore posing additional global threats in the attempt to control the viral spread as well as threatening the success of vaccination strategies.
FluoroType® SARS-CoV-2 varID Q is a multiplex PCR test for detection and quantification of SARS-CoV-2 and simultaneous identification of four different S gene mutations of SARS-CoV-2.
Two independent genes of the SARS-CoV-2 genome are targeted, providing confident identification of SARS-CoV-2. Viral load assessment according to the NIBSC First WHO International Standard for SARS-CoV-2 RNA (in IU/ml) helps to monitor disease progression.
Four different S gene mutations of SARS-CoV-2 are differentiated via melting curve analysis: N501Y, del69-70, D80A and E484K.
The test is validated for use with nasopharyngeal and oropharyngeal swabs and contains reagents for up to 96 reactions. PCR results are produced in under two hours. Elaborate Internal Controls monitor extraction, reverse-transcription and amplification for maximum confidence.
Automatically generated reports allow for fast, confident reporting without the need for individual interpretation. The wizard-based software comfortably guides users through setup and results evaluation.
Together with the nucleic acid extraction solutions GenoXtract® or GenoXtract® fleXT, the system provides a fully validated workflow for ease of implementation in your laboratory.
Hain Lifescience GmbH - a Bruker company
Hain Lifescience Spain SL - a Bruker Company
Biocentric - a Bruker Company
Bruker UK Ltd.